STOCK TITAN

Bicycle Therapeutics Plc - BCYC STOCK NEWS

Welcome to our dedicated news page for Bicycle Therapeutics Plc (Ticker: BCYC), a resource for investors and traders seeking the latest updates and insights on Bicycle Therapeutics Plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Bicycle Therapeutics Plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Bicycle Therapeutics Plc's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.34%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.28%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.24%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.01%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.19%
Tags
conferences
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.34%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.75%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.49%
Tags
Bicycle Therapeutics Plc

Nasdaq:BCYC

BCYC Rankings

BCYC Stock Data

832.62M
6.17%
91.75%
6.71%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United Kingdom
Cambridge

About BCYC

bicycle therapeutics is a biotechnology company with big ambitions. we aim to revolutionise the pharmaceutical landscape with our disruptive technology and proprietary bicyclic peptide (bicycle®) product platform and to develop transformational new therapies for patients to improve future treatment options in oncology. bicycles, a new class of small molecular weight drug conjugates for oncology and other diseases, are designed to have superior targeting abilities and to be more efficacious and better tolerated than existing drug conjugate modalities. they combine the properties of several therapeutic entities in a single modality, exhibiting the affinity and selective pharmacology associated with antibodies; the distribution kinetics of small molecules, allowing rapid tumor penetration; and the “tuneable” pharmacokinetic half-life and renal clearance of peptides, sparing cytotoxin-payload derived liver and gastrointestinal toxicity. our unique ip is based on the work of scientific foun